[
  {
    "objectID": "kq6.html",
    "href": "kq6.html",
    "title": "Delirium Prophylaxis",
    "section": "",
    "text": "Among older patients undergoing surgery and anesthesia, do dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes?"
  },
  {
    "objectID": "kq6.html#outcome-importance-rankings",
    "href": "kq6.html#outcome-importance-rankings",
    "title": "Delirium Prophylaxis",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1.  Rankings for the 5 most important outcomes (11 respondents).\n\n\n\n\n\n\n\n\nReporting Frequency\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Outcome\n      RCT, N = 76\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 1\n    \n  \n  \n    ADL\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Complications\n29 (38%)\n2 (67%)\n2 (100%)\n0 (0%)\n    Delayed NCR/NCD\n24 (32%)\n2 (67%)\n0 (0%)\n0 (0%)\n    Delirium\n45 (59%)\n0 (0%)\n2 (100%)\n1 (100%)\n    Delirium duration\n3 (3.9%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Depression\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Discharge location\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Mortality\n16 (21%)\n0 (0%)\n1 (50%)\n0 (0%)\n    Opioid use\n4 (5.3%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Pain\n2 (2.6%)\n0 (0%)\n0 (0%)\n0 (0%)\n    QoR\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Readmission\n2 (2.6%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Satisfaction\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; NCD: neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Outcome\n      RCT, N = 76\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 1\n    \n  \n  \n    6-minute walk\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Delirium duration\n14 (18%)\n0 (0%)\n1 (50%)\n0 (0%)\n    Grip strength\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Length of stay\n26 (34%)\n0 (0%)\n2 (100%)\n1 (100%)\n    Opioid use\n13 (17%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Pulmonary function\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Outcome\n      RCT, N = 76\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 1\n    \n  \n  \n    ADL\n2 (2.6%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Delayed NCR/NCD\n34 (45%)\n3 (100%)\n0 (0%)\n0 (0%)\n    Delirium\n4 (5.3%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Complications\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Depression/anxiety\n6 (7.9%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Pain\n18 (24%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Quality of life\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n    QoR\n2 (2.6%)\n0 (0%)\n0 (0%)\n0 (0%)\n    Satisfaction\n0 (0%)\n0 (0%)\n0 (0%)\n0 (0%)\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; NCD: neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort."
  },
  {
    "objectID": "kq6.html#included-studies",
    "href": "kq6.html#included-studies",
    "title": "Delirium Prophylaxis",
    "section": "Included Studies",
    "text": "Included Studies\n Table 5. Number of studies by design. \n\n\n\n\n\n\n\n  \n    \n    \n  \n  \n  \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n74\n    Nonrandomized Trial\n3\n    Before-After/Time Series\n2\n    Prospective Cohort\n1\n    Total\n80\n  \n  \n  \n    \n       Counted randomized clinical trials with more than 1 publication only once (applied to 2 trials with 2 publications).\n    \n  \n\n\n\n\n\nDesign, centers, country, and surgery\n Table 6. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Surgeryb\n    \n  \n  \n    \n      Dexmedetomidine - Randomized Clinical Trial\n    \n    13579\nAzeem 2018\n\n1\n70\nEgypta\nCardiac\n    7240\nChitnis 2022\n\n1\n70\nCanada\nCardiac\n    2288\nDjainai 2016\n\n1\n185\nCanada\nCardiac\n    1819\nGao 2020\n\n1\n60\nChinaa\nCardiac\n    5269\nGao 2021\n\n1\n40\nChinaa\nCardiac\n    13777\nGe 2016\n\n1\n50\nChinaa\nCardiac\n    24\nLi 2017\n\n2\n285\nChinaa\nCardiac\n    13171\nMahrose 2021\n\n1\n110\nEgypta\nCardiac\n    2173\nMomeni 2021\n\n1\n420\nBelgium\nCardiac\n    2396\nShehabi 2009\n\n2\n306\nAustralia\nCardiac\n    18\nShi 2019\n\n3\n168\nChinaa\nCardiac\n    2624\nSubramaniam 2019\n\n1\n140\nUSA\nCardiac\n    16008\nTuran 2020\n\n6\n798\nUSA\nCardiac\n    16023\nWu 2020\n\n1\n80\nChinaa\nCardiac\n    13406\nZhou 2019b\n\n1\n156\nChinaa\nCardiac\n    335\nvan Norden 2021\n\n1\n63\nGermany\nCardiac|GI/Abdominal\n    5436\nChen 2013\n\n1\n126\nChinaa\nGI/Abdominal\n    889\nChen 2020\n\n1\n88\nChinaa\nGI/Abdominal\n    1288\nDu 2019\n\n1\n87\nChinaa\nGI/Abdominal\n    13734\nFan 2017b\n\n1\n76\nChinaa\nGI/Abdominal\n    5024\nLi 2015\n\n1\n100\nChinaa\nGI/Abdominal\n    4914\nLi 2021b\n\n1\n120\nChinaa\nGI/Abdominal\n    13941\nMohamed 2014\n\n1\n58\nEgypta\nGI/Abdominal\n    12900\nTang 2021b\n\n1\n100\nChinaa\nGI/Abdominal\n    1919\nXin 2021\n\n1\n60\nChinaa\nGI/Abdominal\n    8558\nLu 2021\n\n13\n808\nChinaa\nGI/Abdominal|Hepatic\n    2318\nSu 2016 (Zhang 2019b)\n\n2\n700\nChinaa\nGI/Abdominal|Neuro|Thoracic|Urol\n    1817\nZhang 2019b (Su 2016)\n\n2\n464\nChinaa\nGI/Abdominal|Neuro|Thoracic|Urol\n    5480\nZhang 2021\n\n1\n174\nChinaa\nGI/Abdominal|Neuro|Urol\n    13483\nWang 2019\n\n1\n198\nChinaa\nGI/Abdominal|Ortho|Thoracic\n    261\nLee 2018a\n\n1\n354\nSouth Korea\nGI/Abdominal|Urol\n    328\nZhang 2018b\n\n1\n120\nChinaa\nHeadneck\n    5240\nHong 2021\n\n2\n712\nChinaa\nNeuro|Ortho\n    1117\nMansouri 2019\n\n1\n150\nIrana\nOptho\n    5452\nGuo 2015\n\n1\n184\nChinaa\nOralmax\n    1625\nWang 2020a\n\n1\n44\nChinaa\nOralmax\n    2748\nLee 2018b\n\n1\n132\nSouth Korea\nOrtho\n    742\nLi 2019\n\n1\n164\nChinaa\nOrtho\n    1419\nLiu 2016\n\n1\n200\nChinaa\nOrtho\n    3130\nLu 2017\n\n1\n152\nChinaa\nOrtho\n    1735\nMei 2018\n\n1\n336\nChinaa\nOrtho\n    1267\nMei 2020\n\n1\n415\nChinaa\nOrtho\n    13075\nXing 2021\n\n1\n110\nChinaa\nOrtho\n    13630\nXuan 2018\n\n3\n453\nChinaa\nOrtho\n    16303\nYan 2021\n\n1\n100\nChinaa\nOrtho\n    5147\nZhang 2020\n\n1\n240\nChinaa\nOrtho\n    11129\nZhu 2021\n\n1\n187\nChinaa\nOrtho\n    13568\nHe 2018\n\n1\n90\nChinaa\nThoracic\n    3046\nHu 2021\n\n1\n177\nChinaa\nThoracic\n    69\nHuyan 2019\n\n1\n360\nChinaa\nThoracic\n    3391\nShi 2020\n\n1\n106\nChinaa\nThoracic\n    13731\nYu 2017\n\n1\n92\nChinaa\nThoracic\n    4798\nDing 2015\n\n1\n40\nChinaa\nUrol\n    7151\nWang 2022\n\n1\n125\nChinaa\nUrol\n    5251\nChawdhary 2020\n\n1\n87\nIndiaa\nVarious\n    2022\nDeiner 2017\n\n10\n429\nUSA\nVarious\n    2314\nSun 2019\n\n1\n618\nChinaa\nVarious\n    3716\nZhao 2020\n\n1\n432\nChinaa\nVarious\n    \n      Dexmedetomidine - Nonrandomized Trial\n    \n    13393\nBao 2020\n\n1\n178\nChinaa\nGI/Abdominal\n    13361\nWang 2020d\n\n1\n110\nChinaa\nGI/Abdominal\n    13301\nLi 2020\n\n1\n87\nChinaa\nThoracic\n    \n      Ketamine - Randomized Clinical Trial\n    \n    181\nHudetz 2009a (Hudetz 2009b)\n\n1\n78\nUSA\nCardiac\n    1847\nHudetz 2009b (Hudetz 2009a)\n\n1\n58\nUSA\nCardiac\n    5189\nSiripoonyothai 2021\n\n1\n75\nThailand\nCardiac\n    2598\nWang 2017\n\n1\n80\nChinaa\nEnt\n    15285\nBornemann-Cimenti 2016\n\n1\n60\nAustria\nGI/Abdominal|Hepatic\n    2217\nRascon-Martinez 2016\n\n1\n80\nMexicoa\nOptho\n    2578\nLee 2015\n\n1\n56\nSouth Korea\nOrtho\n    13184\nTu 2021\n\n1\n80\nChinaa\nOrtho\n    2866\nAvidan 2017\n\n5\n672\nUSA\nVarious\n    1937\nHollinger 2021\n\n2\n143\nSwitzerland\nVarious\n    \n      Ketamine - Prospective Cohort\n    \n    9616\nBarreto Chang 2022\n\n1\n98\nUSA\nSpine\n    \n      Melatonin - Randomized Clinical Trial\n    \n    16558\nFord 2020\n\n2\n210\nAustralia\nCardiac\n    9256\nJavaherforoosh 2021\n\n1\n60\nIrana\nCardiac\n    9741\nShi 2021\n\n1\n297\nChinaa\nCardiac\n    602\nFan 2017a\n\n1\n148\nChinaa\nOrtho\n    5164\nSultan 2010\n\n1\n152\nEgypta\nOrtho\n    16552\nde Jonghe 2014\n\n3\n452\nNetherlands\nOrtho\n    \n      Ramelteon - Randomized Clinical Trial\n    \n    13546\nZhang 2018c\n\n1\n60\nChinaa\nNeuro\n    13512\nGupta 2019\n\n1\n100\nIndiaa\nVarious\n    \n      Ramelteon - Before-After/Time Series\n    \n    693\nHokuto 2020\n\n1\n309\nJapan\nHepatic\n    2997\nMiyata 2017\n\n1\n82\nJapan\nThoracic\n  \n  \n  \n    \n       GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n    \n      a Non very-high Human Development Index country.\n    \n    \n      b Various indicates more than 4 different types of surgery.\n    \n  \n\n\n\n\n\nCountry Summary\n Table 7. Summary of studies by country where conducted. \n\n\n\n\n\n\n  \n  \n    \n      \n      N = 82a\n    \n  \n  \n    Country\n\n        China\n51 (62%)\n        USA\n7 (8.5%)\n        Egypt\n4 (4.9%)\n        South Korea\n3 (3.7%)\n        Australia\n2 (2.4%)\n        Canada\n2 (2.4%)\n        India\n2 (2.4%)\n        Iran\n2 (2.4%)\n        Japan\n2 (2.4%)\n        Austria\n1 (1.2%)\n        Belgium\n1 (1.2%)\n        Germany\n1 (1.2%)\n        Mexico\n1 (1.2%)\n        Netherlands\n1 (1.2%)\n        Switzerland\n1 (1.2%)\n        Thailand\n1 (1.2%)\n  \n  \n  \n    \n      a n (%)"
  },
  {
    "objectID": "kq6.html#interventions-and-comparators",
    "href": "kq6.html#interventions-and-comparators",
    "title": "Delirium Prophylaxis",
    "section": "Interventions and Comparators",
    "text": "Interventions and Comparators\n\nDexmedetomidine\n Table 8. Selected characteristics, comparators, and dosing in dexmedetomidine trials. \n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      \n        Dexmedetomidine Dose mcg/kg\n      \n      Pre\n      Ind\n      Intr\n      Post\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n      Loading\n      Maintenance/hrc\n      Postop\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Shehabi 2009\n\n147\nMS\n—\n✓\n\n\n\n71.0 {65-75}\n\n\n\n\n\n\n\n\n\n    \n152\nDex\n\n\n\n\n\n71.5 {66-76}\n\n\n\n(0.1–0.7)\n\n\n\n\n▂\n\n    Djainai 2016\n\n92\nProp\n—\n✓\n\n\n\n72.4 (6.2)\n\n\n\n\n\n\n\n\n\n    \n91\nDex\n\n\n\n\n\n72.7 (6.4)\n\n\n0.4\n(0.2–0.7)\n\n\n\n\n▂\n\n    Ge 2016\n\n24\nPlac\n123 \n\n✓\n\n\n72.0 (4.0)\n\n27 (0.8)\n\n\n\n\n\n\n\n\n    \n24\nDex\n\n\n\n\n\n70.0 (3.0)\n\n27 (0.9)\n\n0.3\n0.3\n\n\n▂\n\n▂\n\n\n    Li 2017\n\n143\nPlac\n 234\n✓\n✓\n\n\n67.5 (5.3)\n\n29 [28-30]\n\n\n\n\n\n\n\n\n    \n142\nDex\n\n\n\n\n\n66.4 (5.4)\n\n29 [28-30]\n\n0.6\n0.4\n0.100\n\n\n▂\n\n▂\n\n    Azeem 2018\n\n30\nMid\n—\n\n✓\n\n\n66.7 (5.6)\n\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n\n\n\n65.3 (4.8)\n\n\n\n(0.4–0.7)\n\n\n▂\n\n\n▂\n\n    Shi 2019\n\n80\nProp\n—\n\n✓\n\n\n74.2 (7.7)\n\n\n\n\n\n\n\n\n\n    \n84\nDex\n\n\n\n\n\n74.7 (7.2)\n\n\n\n(0.4–0.6)\n\n\n\n▂\n\n\n    Subramaniam 2019\n\n61\nProp\n—\n\n\n\n\n70.0 {64-79}\n\n\n\n\n\n\n\n\n\n    \n59\nDex\n\n\n\n\n\n66.5 {63-74}\n\n\n0.5\n(0.1–0.4)\n\n\n\n\n▂\n\n    Zhou 2019b\n\n39\nUlin\n123 \n✓\n✓\n\n\n70.6 (4.4)\n\n\n\n\n\n\n\n\n\n    \n38\nPlac\n\n\n\n\n\n70.0 (4.9)\n\n\n\n\n\n\n\n\n\n    \n38\nDex\n\n\n\n\n\n69.8 (5.1)\n\n\n\n0.4\n\n\n\n▂\n\n\n    \n39\nDex/Ulin\n\n\n\n\n\n69.6 (5.0)\n\n\n\n0.4\n\n\n\n▂\n\n\n    Gao 2020\n\n30\nPlac\n 23 \n\n✓\n\n\n70.4 (4.2)\n\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n\n\n\n69.5 (5.1)\n\n\n1.0\n(0.3–0.5)\n\n\n▂\n\n▂\n\n\n    Turan 2020\n\n396\nPlac\n1234\n✓\n✓\n\n\n62.0 (12.0)\n\n\n\n\n\n\n\n\n\n    \n398\nDex\n\n\n\n\n\n63.0 (11.0)\n\n\n\n0.1\n0.400\n\n▂\n\n▂\n\n▂\n\n    Wu 2020\n\n40\nPlac\n 23 \n\n\n\n✓\n67.7 (8.8)\n\n27\n\n\n\n\n\n\n\n\n    \n40\nDex\n\n\n\n\n\n68.2 (8.6)\n\n27\n\n0.5\n0.6\n\n\n▂\n\n▂\n\n\n    Gao 2021\n\n20\nPlac\n 23 \n\n✓\n\n\n71.4 (4.5)\n\n28 (1.3)\n\n\n\n\n\n\n\n\n    \n20\nDex\n\n\n\n\n\n71.4 (4.5)\n\n28 (1.4)\n\n0.6\n0.2\n\n\n▂\n\n▂\n\n\n    Mahrose 2021\n\n55\nDex\n—\n✓\n✓\n\n\n67.0 (6.7)\n\n\n0.4\n(0.2–0.7)\n\n▂\n\n\n\n▂\n\n    \n55\nDex\n\n\n\n\n\n66.1 (6.3)\n\n\n0.4\n(0.2–0.7)\n\n\n\n\n▂\n\n    Momeni 2021\n\n172\nPlac\n—\n✓\n\n\n\n70.0 {59-81}\n\n28 {26-29}\n\n\n\n\n\n\n\n\n    \n177\nDex\n\n\n\n\n\n71.0 {61-81}\n\n28 {26-29}\n\n\n0.4\n\n\n\n\n▂\n\n    Chitnis 2022\n\n33\nProp\n—\n✓\n\n\n\n78.8\n\n29\n\n\n\n\n\n\n\n\n    \n33\nDex\n\n\n\n\n\n78.7\n\n29\n\n\n0.5 (0–1.5)\n\n\n\n\n▂\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Liu 2016 (MCI)\n\n40\nPlac\n 23 \n\n✓\n\n\n75.2 (7.8)\n\n22 (2.6)\n\n\n\n\n\n\n\n\n    \n39\nDex\n\n\n\n\n\n72.8 (8.2)\n\n23 (2.7)\n\n\n(0.2–0.4)\n\n\n\n▂\n\n\n    Liu 2016 (no MCI)\n\n58\nPlac\n 23 \n\n✓\n\n\n72.8 (9.2)\n\n25 (2.4)\n\n\n\n\n\n\n\n\n    \n60\nDex\n\n\n\n\n\n71.2 (8.1)\n\n26 (3.5)\n\n\n(0.2–0.4)\n\n\n\n▂\n\n\n    Lu 2017\n\n76\nDex\n 23 \n\n✓\n✓\n\n65.0 (5.8)\n\n28 (1.3)\n\n0.5\n0.5\n\n\n▂\n\n▂\n\n\n    \n75\nDex\n\n\n\n\n\n65.5 (5.3)\n\n28 (1.2)\n\n0.5\n0.5\n0.060\n\n▂\n\n▂\n\n▂\n\n    Lee 2018b\n\n31\nPlac\n12  \n\n\n✓\n\n67.2 (5.0)\n\n\n\n\n\n\n\n\n\n    \n33\nPreg\n\n\n\n\n\n68.4 (5.1)\n\n\n\n\n\n\n\n\n\n    \n31\nDex\n\n\n\n\n\n68.8 (5.9)\n\n\n0.5\n0.5\n\n\n▂\n\n▂\n\n\n    \n29\nDex/Preg\n\n\n\n\n\n65.4 (9.7)\n\n\n0.5\n0.5\n\n\n▂\n\n▂\n\n\n    Mei 2018\n\n148\nProp\n 23 \n\n\n✓\n\n74.0 (6.0)\n\n26 (1.7)\n\n\n\n\n\n\n\n\n    \n148\nDex\n\n\n\n\n\n76.0 (7.0)\n\n26 (2.1)\n\n0.9\n(0.1–0.5)\n\n\n▂\n\n\n\n    Xuan 2018\n\n226\nPlac\n—\n\n✓\n\n\n66.9 (5.1)\n\n\n\n\n\n\n\n\n\n    \n227\nDex\n\n\n\n\n\n66.6 (7.5)\n\n\n\n0.1\n\n\n\n\n\n    Li 2019\n\n55\nProp\n123 \n\n\n✓\n\n68.2 (6.4)\n\n\n\n\n\n\n\n\n\n    \n54\nMid\n\n\n\n\n\n66.9 (6.6)\n\n\n\n\n\n\n\n\n\n    \n55\nDex\n\n\n\n\n\n69.3 (7.1)\n\n\n\n\n\n\n\n▂\n\n\n    Mei 2020\n\n183\nProp\n—\n\n\n✓\n\n73.0 (11.0)\n\n27 (1.4)\n\n\n\n\n\n\n\n\n    \n183\nDex\n\n\n\n\n\n72.0 (9.0)\n\n27 (2.9)\n\n0.9\n(0.1–0.5)\n\n\n\n▂\n\n\n    Zhang 2020\n\n120\nPlac\n123 \n\n\n✓\n\n79.0 (6.8)\n\n\n\n\n\n\n\n\n\n    \n120\nDex\n\n\n\n\n\n78.1 (6.4)\n\n\n0.5\n0.3\n\n▂\n\n\n▂\n\n\n    Xing 2021\n\n55\nPlac\n 23 \n✓\n\n\n\n69.2 (3.8)\n\n\n\n\n\n\n\n\n\n    \n55\nDex\n\n\n\n\n\n68.3 (3.9)\n\n\n0.5\n\n\n\n▂\n\n\n\n    Yan 2021\n\n50\nPlac\n12  \n\n✓\n\n\n72.7 (4.3)\n\n29 (0.3)\n\n\n\n\n\n\n\n\n    \n50\nDex\n\n\n\n\n\n73.2 (5.8)\n\n30 (0.2)\n\n\n0.3\n\n\n▂\n\n\n\n    Zhu 2021\n\n92\nPlac\n123 \n\n\n✓\n\n75.2 (6.1)\n\n29 (0.9)\n\n\n\n\n\n\n\n\n    \n95\nDex\n\n\n\n\n\n74.1 (4.4)\n\n29 (0.8)\n\n1.0\n0.5\n\n▂\n\n\n▂\n\n\n    \n      Various - Randomized Clinical Trial\n    \n    Su 2016\n\n350\nPlac\n 23 \n\n✓\n\n\n74.2 (6.8)\n\n\n\n\n\n\n\n\n\n    \n350\nDex\n\n\n\n\n\n74.2 (6.6)\n\n\n\n0.1\n\n\n\n\n▂\n\n    Deiner 2017\n\n201\nPlac\n1234\n✓\n✓\n\n\n74.0 {71-78}\n\n\n\n\n\n\n\n\n\n    \n189\nDex\n\n\n\n\n\n74.0 {71-78}\n\n\n\n0.5\n\n▂\n\n\n▂\n\n▂\n\n    Lee 2018a\n\n109\nPlac\n123 \n✓\n\n\n\n73.1 (6.1)\n\n\n\n\n\n\n\n\n\n    \n95\nDex\n\n\n\n\n\n72.2 (5.4)\n\n\n1.0\n(0.2–0.7)\n\n\n▂\n\n▂\n\n\n    \n114\nDex\n\n\n\n\n\n73.1 (6.4)\n\n\n1.0\n\n\n\n\n▂\n\n\n    Sun 2019\n\n276\nPlac\n123 \n\n✓\n\n\n69.0 {65-74}\n\n24 {22-26}\n\n\n\n\n\n\n\n\n    \n281\nDex\n\n\n\n\n\n68.0 {66-73}\n\n25 {22-27}\n\n\n4.8\n0.100\n\n\n\n▂\n\n    Wang 2019\n\n100\nMid\n123 \n\n✓\n\n\n69.4 (4.5)\n\n25 (3.3)\n\n\n\n\n\n\n\n\n    \n98\nDex\n\n\n\n\n\n70.5 (5.0)\n\n25 (3.9)\n\n0.5\n\n\n▂\n\n\n\n\n    Zhang 2019b\n\n213\nPlac\n 23 \n\n✓\n\n\n74.2 (6.8)\n\n\n\n\n\n\n\n\n\n    \n221\nDex\n\n\n\n\n\n74.2 (6.6)\n\n\n\n0.1\n\n\n\n\n▂\n\n    Chawdhary 2020\n\n40\nProp\n123 \n✓\n\n\n\n64.7 (5.9)\n\n26 (1.3)\n\n\n\n\n\n\n\n\n    \n40\nDex\n\n\n\n\n\n66.2 (6.6)\n\n26 (1.2)\n\n\n(0.5–0.7)\n\n\n\n▂\n\n\n    Zhao 2020\n\n101\nNone\n 23 \n\n✓\n\n\n69.2 (4.1)\n\n27 {24-30}\n\n\n\n\n\n\n\n\n    \n108\nDex\n\n\n\n\n\n70.0 (4.5)\n\n27 {24-30}\n\n1.0\n100d\n\n\n▂\n\n▂\n\n\n    \n105\nDex\n\n\n\n\n\n69.4 (3.9)\n\n27 {24-30}\n\n1.0\n200d\n\n\n▂\n\n▂\n\n\n    \n102\nDex\n\n\n\n\n\n69.3 (4.1)\n\n27 {24-30}\n\n1.0\n400d\n\n\n▂\n\n▂\n\n\n    Hong 2021\n\n354\nPlac\n1234\n✓\n\n✓\n\n71.0 (5.0)\n\n26 (3.0)\n\n\n\n\n\n\n\n\n    \n356\nDex\n\n\n\n\n\n71.0 (5.0)\n\n26 (2.9)\n\n\n\n0.026\n\n\n\n▂\n\n    Zhang 2021\n\n87\nPlac\n 23 \n✓\n\n\n\n71.4 (4.9)\n\n26 (0.8)\n\n\n\n\n\n\n\n\n    \n87\nDex\n\n\n\n\n\n70.6 (4.2)\n\n26 (0.7)\n\n1.0\n0.4\n\n\n▂\n\n▂\n\n\n    van Norden 2021\n\n32\nPlac\n1234\n\n✓\n\n\n70.5 (6.2)\n\n\n\n\n\n\n\n\n\n    \n28\nDex\n\n\n\n\n\n70.4 (7.1)\n\n\n0.7\n\n\n\n\n▂\n\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Chen 2013\n\n63\nPlac\n—\n\n✓\n\n\n67.9 (6.6)\n\n28 (1.1)\n\n\n\n\n\n\n\n\n    \n59\nDex\n\n\n\n\n\n66.2 (7.5)\n\n28 (0.8)\n\n1.0\n0.4\n\n\n▂\n\n▂\n\n\n    Mohamed 2014\n\n25\nPlac\n123 \n✓\n✓\n\n\n67.8 (5.4)\n\n\n\n\n\n\n\n\n\n    \n25\nDex\n\n\n\n\n\n63.9 (5.0)\n\n\n0.17\n0.4\n\n▂\n\n▂\n\n▂\n\n\n    Li 2015\n\n50\nPlac\n123 \n✓\n\n\n\n70.0 (6.0)\n\n28 (1.4)\n\n\n\n\n\n\n\n\n    \n50\nDex\n\n\n\n\n\n69.0 (5.0)\n\n28 (1.3)\n\n1.0\n0.4\n\n\n▂\n\n▂\n\n\n    Fan 2017b\n\n38\nRhyth\n—\n\n✓\n\n\n68.4 (2.3)\n\n\n\n\n\n\n\n\n\n    \n38\nDex\n\n\n\n\n\n69.2 (2.4)\n\n\n1.0\n(0.2–0.7)\n\n\n\n\n\n    Du 2019\n\n20\nPlac\n12  \n✓\n\n\n\n68.7 (13.5)\n\n27 (1.5)\n\n\n\n\n\n\n\n\n    \n20\nDex\n\n\n\n\n\n69.3 (12.5)\n\n26 (1.7)\n\n\n0.6\n\n\n\n▂\n\n\n    Chen 2020\n\n45\nPlac\n12  \n\n✓\n\n\n65.4 (11.7)\n\n29 (0.4)\n\n\n\n\n\n\n\n\n    \n43\nDex\n\n\n\n\n\n64.9 (11.4)\n\n29 (0.5)\n\n0.3\n1\n\n\n\n▂\n\n\n    Li 2021b\n\n30\nPlac\n123 \n\n✓\n\n\n73.4 (5.1)\n\n29 (2.1)\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n\n\n\n74.7 (2.6)\n\n28 (3.2)\n\n0.3\n0.2\n\n▂\n\n\n▂\n\n\n    \n30\nDex\n\n\n\n\n\n71.2 (3.5)\n\n28 (1.7)\n\n0.3\n0.5\n\n▂\n\n\n▂\n\n\n    \n30\nDex\n\n\n\n\n\n69.8 (4.3)\n\n28 (2.6)\n\n0.3\n0.8\n\n▂\n\n\n▂\n\n\n    Lu 2021\n\n331\nPlac\n123 \n\n✓\n\n\n70.4 (6.5)\n\n\n\n\n\n\n\n\n\n    \n344\nDex\n\n\n\n\n\n70.1 (5.8)\n\n\n0.5\n0.2\n\n\n▂\n\n▂\n\n\n    Tang 2021b\n\n50\nPlac\n12  \n✓\n✓\n\n\n70.7 (6.5)\n\n\n\n\n\n\n\n\n\n    \n50\nDex\n\n\n\n\n\n69.7 (6.6)\n\n\n0.5\n0.4\n\n\n▂\n\n▂\n\n\n    Xin 2021\n\n30\nPlac\n 23 \n\n✓\n\n\n68.0 [66-71]\n\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n\n\n\n69.0 [67-70]\n\n\n0.5\n0.4\n\n▂\n\n\n▂\n\n\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Yu 2017\n\n46\nMid\n12  \n\n✓\n\n\n69.1 (4.9)\n\n30 (0.7)\n\n\n\n\n\n\n\n\n    \n46\nDex\n\n\n\n\n\n68.7 (4.3)\n\n30 (0.7)\n\n0.2\n0.5 (0.2–0.7)\n\n\n▂\n\n▂\n\n\n    He 2018\n\n30\nPlac\n123 \n✓\n✓\n\n\n83.2 (5.1)\n\n\n\n\n\n\n\n\n\n    \n30\nMid\n\n\n\n\n\n81.9 (6.2)\n\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n\n\n\n82.5 (5.4)\n\n\n0.5\n0.4\n\n▂\n\n▂\n\n▂\n\n\n    Huyan 2019\n\n173\nPlac\n 23 \n\n✓\n\n\n71.0 (6.0)\n\n\n\n\n\n\n\n\n\n    \n173\nDex\n\n\n\n\n\n70.0 (5.0)\n\n\n0.5\n0.1\n\n▂\n\n\n▂\n\n\n    Shi 2020\n\n53\nPlac\n 23 \n\n✓\n✓\n\n68.7 (3.4)\n\n28 (0.9)\n\n\n\n\n\n\n\n\n    \n53\nDex\n\n\n\n\n\n68.7 (4.6)\n\n28 (0.9)\n\n\n0.5\n\n\n▂\n\n▂\n\n\n    Hu 2021\n\n87\nPlac\n123 \n\n✓\n\n\n69.1 (5.1)\n\n\n\n\n\n\n\n\n\n    \n90\nDex\n\n\n\n\n\n69.6 (4.5)\n\n\n0.4\n0.1\n\n\n▂\n\n▂\n\n\n    \n      Oralmax - Randomized Clinical Trial\n    \n    Guo 2015\n\n73\nPlac\n123 \n✓\n\n\n\n71.3 (5.1)\n\n28 (1.6)\n\n\n\n\n\n\n\n\n    \n76\nDex\n\n\n\n\n\n70.7 (5.2)\n\n28 (1.6)\n\n\n\n0.200\n\n\n\n▂\n\n    Wang 2020a\n\n20\nMid\n—\n\n✓\n\n\n60.5 (8.2)\n\n\n\n\n\n\n\n\n\n    \n20\nDex\n\n\n\n\n\n60.0 (10.1)\n\n\n1.0\n(0.2–0.7)\n\n\n▂\n\n▂\n\n\n    \n      Urol - Randomized Clinical Trial\n    \n    Ding 2015\n\n20\nPlac\n—\n✓\n\n\n\n\n\n\n\n\n\n\n\n\n    \n20\nDex\n\n\n\n\n\n\n\n2\n\n\n\n▂\n\n\n\n    Wang 2022\n\n60\nPlac\n12  \n\n✓\n\n\n66.7 (4.1)\n\n25 (2.2)\n\n\n\n\n\n\n\n\n    \n60\nDex\n\n\n\n\n\n65.6 (3.4)\n\n26 (2.5)\n\n\n0.4\n\n\n▂\n\n\n\n    \n      Headneck - Randomized Clinical Trial\n    \n    Zhang 2018b\n\n30\nMid/Prop\n—\n\n✓\n\n\n69.9 (2.8)\n\n29 (1.2)\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n✓\n\n\n\n69.3 (3.1)\n\n29 (1.1)\n\n1.0\n0.5\n\n\n▂\n\n▂\n\n\n    \n30\nMid/Sevo\n\n✓\n\n\n\n70.1 (3.2)\n\n29 (1.2)\n\n\n\n\n\n\n\n\n    \n30\nDex\n\n\n✓\n\n\n68.8 (3.0)\n\n29 (0.9)\n\n1.0\n0.5\n\n\n▂\n\n▂\n\n\n    \n      Ophtho - Randomized Clinical Trial\n    \n    Mansouri 2019\n\n50\nPlac\n12  \n\n✓\n\n\n64.0 (7.2)\n\n\n\n\n\n\n\n\n\n    \n50\nMid\n\n\n\n\n\n63.6 (8.3)\n\n\n\n\n\n\n\n\n\n    \n50\nDex\n\n\n\n\n\n66.5 (1.6)\n\n\n\n1\n\n\n\n▂\n\n\n    \n      GI/Abd - Nonrandomized Trial\n    \n    Bao 2020\n\n83\nDex\n—\n\n✓\n\n\n64.9 (5.7)\n\n26\n\n0.5\n0.3\n\n\n▂\n\n▂\n\n\n    \n95\nDex/Ulin\n\n\n\n\n\n65.3 (5.7)\n\n26 (0.2)\n\n0.5\n0.3\n\n\n▂\n\n▂\n\n\n    Wang 2020d\n\n50\nPlac\n—\n✓\n✓\n\n\n68.3 (2.1)\n\n28 (4.2)\n\n\n\n\n\n\n\n\n    \n60\nDex\n\n\n\n\n\n68.4 (3.3)\n\n29 (4.3)\n\n0.5\n0.4\n\n▂\n\n\n\n\n    \n      Thoracic - Nonrandomized Trial\n    \n    Li 2020\n\n46\nNone\n—\n\n✓\n\n\n67.3 (2.1)\n\n28 (4.2)\n\n\n\n\n\n\n\n\n    \n41\nDex\n\n\n\n\n\n67.4 (3.3)\n\n29 (4.3)\n\n0.5\n0.1\n\n\n\n▂\n\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Oralmax: oral and maxillofacial; Ophtho; ophthalmologic; Dex: Dexmedetomidine; Uli: Ulinastatin; Hal: Haloperidol; Mid: Midazolam; Mid/Prop: Midazolam/propofol; Mid/Seve: Midazolam/sevoflurane; Preg: Pregabalin; Prop: Propofol; Rhyth: Rhythim; Plac; placebo; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; MMSE: Mini-Mental State Exam; Pre: preoperative; Ind: induction; Intr: intraoperative; Post(op): postoperative; —: unspecified.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD) [Range] {IQR}.\n    \n    \n      c Range if reported in parentheses.\n    \n    \n      d Given as a single dose.\n    \n  \n\n\n\n\n\n\nKetamine\n Table 9. Selected characteristics, comparators, and dosing in ketamine studies. \n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      \n        Dose\n      \n      \n        Maintenance\n      \n      Pre\n      Ind\n      Intr\n      Post\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      (mg/kg)\n        (mg/kg)\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Hudetz 2009a\n\n26\nNone\n—\n✓\n\n\n64.0 (7.0)\n\n\n\n\n\n\n\n\n    \n26\nPlacebo\n\n\n\n\n67.0 (8.0)\n\n\n\n\n\n\n\n\n    \n26\nKetamine\n\n\n\n\n68.0 (7.0)\n\n\n0.5\n\n\n▂\n\n\n\n    Hudetz 2009b\n\n29\nPlacebo\n  34\n✓\n\n\n60.8 (8.0)\n\n\n\n\n\n\n\n\n    \n29\nKetamine\n\n\n\n\n68.0 (8.0)\n\n\n0.5\n\n\n▂\n\n\n\n    Siripoonyothai 2021\n\n32\nOther\n—\n✓\n\n\n\n\n\n\n\n\n\n\n    \n32\nKetamine\n\n\n\n\n\n\n\n1.000\n\n▂\n\n▂\n\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Lee 2015\n\n26\nPlacebo\n123 \n✓\n\n\n68.4 (6.5)\n\n26 {24-28}\n\n\n\n\n\n\n\n    \n25\nKetamine\n\n\n\n\n68.3 (5.3)\n\n25 {24-28}\n\n0.5\n\n\n▂\n\n\n\n    Tu 2021\n\n40\nOther\n123 \n\n✓\n\n65.3 (5.2)\n\n\n\n\n\n\n\n\n    \n40\nKetaminec\n\n\n\n\n66.0 (5.3)\n\n\n0.5\n\n\n▂\n\n\n\n    \n      Various - Randomized Clinical Trial\n    \n    Avidan 2017\n\n217\nPlacebo\n—\n\n\n\n70.0 (6.9)\n\n\n\n\n\n\n\n\n    \n221\nKetamine\n\n\n\n\n70.0 (7.2)\n\n\n0.5\n\n\n\n▂\n\n\n    \n216\nKetamine\n\n\n\n\n70.0 (7.3)\n\n\n1\n\n\n\n\n\n    Hollinger 2021\n\n44\nPlacebo\n—\n\n\n\n74.8 (6.6)\n\n28 (2.3)\n\n\n\n\n\n\n\n    \n45\nHaloperidol\n\n\n\n\n73.4 (6.3)\n\n28 (1.3)\n\n\n\n\n\n\n\n    \n47\nKetamine\n\n\n\n\n73.4 (6.1)\n\n28 (1.7)\n\n1\n\n▂\n\n\n\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Bornemann-Cimenti 2016\n\n19\nPlacebo\n123 \n✓\n✓\n\n61.0 (12.4)\n\n\n\n\n\n\n\n\n    \n19\nKetaminec\n\n\n\n\n58.4 (8.1)\n\n\n\n0.015\n\n\n▂\n\n▂\n\n    \n18\nKetaminec\n\n\n\n\n62.2 (9.8)\n\n\n0.25\n0.125\n\n\n▂\n\n▂\n\n    \n      Ophtho - Randomized Clinical Trial\n    \n    Rascon-Martinez 2016\n\n32\nPlacebo\n123 \n\n\n✓\n70.5 (4.7)\n\n\n\n\n\n\n\n\n    \n33\nKetamine\n\n\n\n\n68.7 (7.1)\n\n\n0.3\n\n\n\n\n\n    \n      Spine - Prospective Cohort\n    \n    Barreto Chang 2022\n\n38\nNone\n123 \n\n\n\n71.0 {68-78}\n\n\n\n\n\n\n\n\n    \n60\nKetamine\n\n\n\n\n70.0 {67-75}\n\n\n\n\n\n\n\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Plac; placebo; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; MMSE: Mini-Mental State Exam; Pre: preoperative; Ind: induction; Intr: intraoperative; Post: postoperative; —: unspecified.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD) [Range] {IQR}.\n    \n    \n      c S-Ketamine.\n    \n  \n\n\n\n\n\n\nMelatonin/Ramelteon\n\n\n\n Table 10. Selected characteristics, comparators, and dosing in Melatonin and ramelteon studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      Dosing\n      Pre\n      Post\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Ford 2020\n\n104\nPlacebo\n—\n\n\n\n67.6 (8.0)\n\n\n\n\n\n    \n98\nMelatonin\n\n\n\n\n69.0 (8.3)\n\n\n3mg × 7\n▂\n\n▂\n\n    Javaherforoosh 2021\n\n30\nPlacebo\n—\n✓\n\n\n62.9 (8.1)\n\n\n\n\n\n    \n30\nMelatonin\n\n\n\n\n60.3 (9.5)\n\n\n3mg × 3\n\n\n    Shi 2021\n\n149\nPlacebo\n—\n\n\n\n71.6 (6.6)\n\n\n\n\n\n    \n148\nMelatonin\n\n\n\n\n71.5 (6.7)\n\n\n3mg × 7\n\n▂\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\n123 \n\n\n✓\n72.3 (6.4)\n\n\n\n\n\n    \n50\nMidazolam\n\n\n\n\n69.9 (8.2)\n\n\n\n\n\n    \n53\nMelatonin\n\n\n\n\n70.4 (7.1)\n\n\n5mg × 2\n▂\n\n\n    de Jonghe 2014\n\n192\nPlacebo\n—\n\n\n\n83.4 (7.5)\n\n23 {10-28}\n\n\n\n\n    \n186\nMelatonin\n\n\n\n\n84.1 (8.0)\n\n23 {12-29}\n\n3mg × 5\n▂\n\n▂\n\n    Fan 2017a\n\n70\nPlacebo\n123 \n\n\n✓\n74.6 (5.4)\n\n27 (0.3)\n\n\n\n\n    \n69\nMelatonin\n\n\n\n\n74.5 (5.7)\n\n27 (0.2)\n\n1mg × 6\n▂\n\n▂\n\n    \n      Various - Randomized Clinical Trial\n    \n    Gupta 2019\n\n50\nPlacebo\n12  \n\n\n✓\n70.6 (3.8)\n\n\n\n\n\n    \n50\nRamelteon\n\n\n\n\n69.3 (4.0)\n\n\n8mg × 2\n▂\n\n\n    \n      GI/Abd - Before-After/Time Series\n    \n    Hokuto 2020\n\n186\nNone\n123 \n\n\n\n69.0 [30-88]\n\n\n\n\n\n    \n120\nRamelteon\n\n\n\n\n71.0 [34-85]\n\n\n8mg × 4\n▂\n\n▂\n\n    \n      Thoracic - Before-After/Time Series\n    \n    Miyata 2017\n\n58\nNone\n—\n✓\n\n✓\n76.5 [70-87]\n\n\n\n\n\n    \n24\nRamelteon\n\n\n\n\n79.0 [70-89]\n\n\n8mg × 7\n\n▂\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; MMSE: Mini-Mental State Exam; Pre: preoperative; Post: postoperative.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD) [Range] {IQR}."
  },
  {
    "objectID": "kq6.html#delirium-incidence",
    "href": "kq6.html#delirium-incidence",
    "title": "Delirium Prophylaxis",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n\n\n\n\n\n\n\n\n\n Figure 1. Delirium incidence by surgical category across all treatment arms in randomized clinical trials. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDexmedetomidine\n Table 11. Delirium incidence and days of ascertainment during hospitalization in trials of dexmedetomidine. \n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n       N\n      Drug\n      Scale\n      Daysa\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      \n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Shehabi 2009\n\n147\nMS\nCAM\n5\n22 (15.0)\n\n\n—\n    \n152\nDex\n\n\n13 (8.6)\n\n\n0.57 (0.30-1.09)\n    Djainai 2016\n\n92\nProp\nCAM\n5\n29 (31.5)\n\n\n—\n    \n91\nDex\n\n\n16 (17.6)\n\n\n0.56 (0.33-0.95)\n    Li 2017\n\n143\nPlac\nCAM\n5\n11 (7.7)\n\n\n—\n    \n142\nDex\n\n\n7 (4.9)\n\n\n0.64 (0.26-1.61)\n    Azeem 2018\n\n30\nMid\nCAM\n7\n1 (3.3)\n\n\n—\n    \n30\nDex\n\n\n2 (6.7)\n\n\n2.00 (0.19-20.90)\n    Shi 2019\n\n80\nProp\nCAM\n5\n21 (26.2)\n\n\n—\n    \n84\nDex\n\n\n33 (39.3)\n\n\n1.50 (0.95-2.36)\n    Subramaniam 2019\n\n61\nProp\nCAM\nStay\n13 (21.3)\n\n\n—\n    \n59\nDex\n\n\n10 (16.9)\n\n\n0.80 (0.38-1.67)\n    Turan 2020\n\n396\nPlac\nCAM\n5\n46 (11.6)\n\n\n—\n    \n398\nDex\n\n\n67 (16.8)\n\n\n1.45 (1.02-2.05)\n    Mahrose 2021\n\n55\nDex\nCAM\n5\n6 (10.9)\n\n\n—\n    \n55\nDex\n\n\n15 (27.3)\n\n\n2.50 (1.05-5.97)\n    Momeni 2021\n\n172\nPlac\nCAM\nStay\n33 (19.2)\n\n\n—\n    \n177\nDex\n\n\n31 (17.5)\n\n\n0.91 (0.59-1.42)\n    Chitnis 2022\n\n33\nProp\nICDSC\n5\n14 (42.4)\n\n\n—\n    \n33\nDex\n\n\n8 (24.2)\n\n\n0.57 (0.28-1.18)\n    \n      Ortho - Randomized Clinical Trial\n    \n    Liu 2016 (MCI)\n\n40\nPlac\nCAM\n7\n25 (62.5)\n\n\n—\n    \n39\nDex\n\n\n10 (25.6)\n\n\n0.41 (0.23-0.74)\n    Liu 2016 (no MCI)\n\n58\nPlac\nCAM\n7\n18 (31.0)\n\n\n—\n    \n60\nDex\n\n\n5 (8.3)\n\n\n0.27 (0.11-0.68)\n    Lee 2018b\n\n31\nPlac\nPsych\nStay\n11 (35.5)\n\n\n—\n    \n33\nPreg\n\n\n14 (42.4)\n\n\n1.20 (0.64-2.22)\n    \n31\nDex\n\n\n3 (9.7)\n\n\n0.27 (0.08-0.88)\n    \n29\nDex/Preg\n\n\n7 (24.1)\n\n\n0.68 (0.31-1.52)\n    Mei 2018\n\n148\nProp\nCAM\n3\n24 (16.2)\n\n\n—\n    \n148\nDex\n\n\n11 (7.4)\n\n\n0.46 (0.23-0.90)\n    Xuan 2018\n\n226\nPlac\nCAM\n7\n64 (28.3)\n\n\n—\n    \n227\nDex\n\n\n30 (13.2)\n\n\n0.47 (0.32-0.69)\n    Mei 2020\n\n183\nProp\nCAM\n7\n43 (23.5)\n\n\n—\n    \n183\nDex\n\n\n26 (14.2)\n\n\n0.60 (0.39-0.94)\n    Zhang 2020\n\n120\nPlac\nCAM/DSM\n3\n36 (30.0)\n\n\n—\n    \n120\nDex\n\n\n20 (16.7)\n\n\n0.56 (0.34-0.90)\n    Xing 2021\n\n55\nPlac\nNoteb\n1\n8 (14.5)\n\n\n—\n    \n55\nDex\n\n\n2 (3.6)\n\n\n0.25 (0.06-1.12)\n    Yan 2021\n\n50\nPlac\nCAM\n7\n13 (26.0)\n\n\n—\n    \n50\nDex\n\n\n5 (10.0)\n\n\n0.38 (0.15-1.00)\n    \n      Various - Randomized Clinical Trial\n    \n    Su 2016\n\n350\nPlac\nCAM\n7\n79 (22.6)\n\n\n—\n    \n350\nDex\n\n\n32 (9.1)\n\n\n0.41 (0.28-0.59)\n    Deiner 2017\n\n201\nPlac\nCAM\n5\n23 (11.4)\n\n\n—\n    \n189\nDex\n\n\n23 (12.2)\n\n\n1.06 (0.62-1.83)\n    Lee 2018a\n\n109\nPlac\nCAM\n5\n27 (24.8)\n\n\n—\n    \n95\nDex\n\n\n9 (9.5)\n\n\n0.38 (0.19-0.77)\n    \n114\nDex\n\n\n21 (18.4)\n\n\n0.74 (0.45-1.23)\n    Sun 2019\n\n276\nPlac\nCAM\n5\n38 (13.8)\n\n\n—\n    \n281\nDex\n\n\n33 (11.7)\n\n\n0.85 (0.55-1.32)\n    Zhao 2020\n\n101\nNone\nCAM\n7\n19 (18.8)\n\n\n—\n    \n108\nDex\n\n\n15 (13.9)\n\n\n0.74 (0.40-1.37)\n    \n105\nDex\n\n\n5 (4.8)\n\n\n0.25 (0.10-0.65)\n    \n102\nDex\n\n\n5 (4.9)\n\n\n0.26 (0.10-0.67)\n    Hong 2021\n\n354\nPlac\nCAM\n5\n26 (7.3)\n\n\n—\n    \n356\nDex\n\n\n17 (4.8)\n\n\n0.65 (0.36-1.18)\n    van Norden 2021\n\n32\nPlac\nCAM/ICDSC\n14\n14 (43.8)\n\n\n—\n    \n28\nDex\n\n\n5 (17.9)\n\n\n0.41 (0.17-0.99)\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Fan 2017b\n\n38\nRhyth\nNS\nStay\n6 (15.8)\n\n\n—\n    \n38\nDex\n\n\n1 (2.6)\n\n\n0.17 (0.02-1.32)\n    Xin 2021\n\n30\nPlac\nCAM\n7\n10 (33.3)\n\n\n—\n    \n30\nDex\n\n\n3 (10.0)\n\n\n0.30 (0.09-0.98)\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Yu 2017\n\n46\nMid\nCAM\n3\n10 (21.7)\n\n\n—\n    \n46\nDex\n\n\n3 (6.5)\n\n\n0.30 (0.09-1.02)\n    Shi 2020\n\n53\nPlac\nCAM\n7\n6 (11.3)\n\n\n—\n    \n53\nDex\n\n\n4 (7.5)\n\n\n0.67 (0.20-2.23)\n    Hu 2021\n\n87\nPlac\nCAM\n4\n32 (36.8)\n\n\n—\n    \n90\nDex\n\n\n15 (16.7)\n\n\n0.45 (0.26-0.78)\n    \n      Oralmax - Randomized Clinical Trial\n    \n    Wang 2020a\n\n20\nMid\nNS\nStay\n9 (45.0)\n\n\n—\n    \n20\nDex\n\n\n1 (5.0)\n\n\n0.11 (0.02-0.80)\n  \n  \n  \n    \n       MMSE: Mini-Mental State Examination; Dex: Dexmedetomidine; Mid: Midazolam; Prop: Propofol; MS: Morphine; Preg: Pregabalin; Prop: Propofol; Rhyth: Rhythim; Plac: placebo; CAM: Confusion Assessment Method; DSM: Diagnostic and Statistical Manual of Mental Disorders; ICDSC: Intensive Care Delirium Screening Checklist; Psych: psychiatrist interview; NS; not specified.\n    \n    \n      a Days over which incidence proportion assessed. Stay indicates over patient hospital stay.\n    \n    \n      b Tool reported in the `Chinese Expert Consensus on the Prevention and Treatment of Postoperative Delirium in Elderly Patients.'\n    \n  \n\n\n\n\n\n\nKetamine\n Table 12. Delirium incidence and days of ascertainment during hospitalization in ketamine studies. \n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n       N\n      Drug\n      Scale\n      Daysa\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      \n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Hudetz 2009b\n\n29\nPlac\nICDSC\n5\n9 (31.0)\n\n\n—\n    \n29\nKet\n\n\n1 (3.4)\n\n\n0.11 (0.02-0.82)\n    Siripoonyothai 2021\n\n32\nProp\nCAM\n1\n18 (56.2)\n\n\n—\n    \n32\nKet\n\n\n10 (31.2)\n\n\n0.56 (0.31-1.01)\n    \n      Various - Randomized Clinical Trial\n    \n    Avidan 2017\n\n217\nPlac\nCAM\n3\n43 (19.8)\n\n\n—\n    \n221\nKet\n\n\n39 (17.6)\n\n\n0.89 (0.60-1.32)\n    \n216\nKet\n\n\n46 (21.3)\n\n\n1.07 (0.74-1.56)\n    Hollinger 2021\n\n44\nPlac\nICDSC\n3\n4 (9.1)\n\n\n—\n    \n45\nHal\n\n\n5 (11.1)\n\n\n1.22 (0.35-4.25)\n    \n47\nKet\n\n\n3 (6.4)\n\n\n0.70 (0.17-2.96)\n    \n      Spine - Prospective Cohort\n    \n    Barreto Chang 2022\n\n38\nNone\nCAM/ICDSC\nStay\n7 (18.4)\n\n\n—\n    \n60\nKet\n\n\n19 (31.7)\n\n\n1.72 (0.80-3.70)\n  \n  \n  \n    \n       MMSE: Mini-Mental State Examination; Ket: ketamine; Plac: placebo; Hal: haloperidol; ICDSC: Intensive Care Delirium Screening Checklist; Psych: psychiatrist interview; NS; not specified.\n    \n    \n      a Days over which incidence proportion assessed. Stay indicates over patient hospital stay.\n    \n  \n\n\n\n\n\n\nMelatonin/Ramelteon\n Table 13. Delirium incidence and days of ascertainment during hospitalization in melatonin and ramelteon studies. \n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Study\n       N\n      Drug\n      Scale\n      Daysa\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      \n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Ford 2020\n\n104\nPlac\nCAM/DSM\n7\n21 (20.2)\n\n\n—\n    \n98\nMel\n\n\n21 (21.4)\n\n\n1.06 (0.62-1.82)\n    Shi 2021\n\n149\nPlac\nCAM\n7\n59 (39.6)\n\n\n—\n    \n148\nMel\n\n\n40 (27.0)\n\n\n0.68 (0.49-0.95)\n    \n      Ortho - Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\nAMT\n3\n16 (32.7)\n\n\n—\n    \n50\nMid\n\n\n22 (44.0)\n\n\n1.35 (0.81-2.24)\n    \n53\nMel\n\n\n5 (9.4)\n\n\n0.29 (0.11-0.73)\n    de Jonghe 2014\n\n192\nPlac\nDSM\n8\n49 (25.5)\n\n\n—\n    \n186\nMel\n\n\n55 (29.6)\n\n\n1.16 (0.83-1.61)\n    \n      Various - Randomized Clinical Trial\n    \n    Gupta 2019\n\n50\nPlac\nCAM\n3\n6 (12.0)\n\n\n—\n    \n50\nRam\n\n\n2 (4.0)\n\n\n0.33 (0.07-1.57)\n    \n      GI/Abd - Before-After/Time Series\n    \n    Hokuto 2020\n\n186\nNone\nDSM\n7\n28 (15.1)\n\n\n—\n    \n120\nRam\n\n\n7 (5.8)\n\n\n0.39 (0.17-0.86)\n    \n      Thoracic - Before-After/Time Series\n    \n    Miyata 2017\n\n58\nNone\nICDSC\n9\n5 (8.6)\n\n\n—\n    \n24\nRam\n\n\n0 (0.0)\n\n\n0.22 (0.01-3.78)\n  \n  \n  \n    \n       MMSE: Mini-Mental State Examination; Mel: melatonin; Ram: ramelteon; AMT: Abbreviated Mental Test; DSM: Diagnostic and Statistical Manual of Mental Disorders; CAM: Confusion Assessment Method; ICDSC: Intensive Care Delirium Screening Checklist.\n    \n    \n      a Days over which incidence proportion assessed. Stay indicates over patient hospital stay.\n    \n  \n\n\n\n\n\n\nMeta-analyses\n\n\n\n\nComparator Network\n Figure 2. Randomized clinical trials and comparators reporting overall incidence of delirium. \n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin or ramelteon; Mid: Midazolam; MS: Morphine sulfate; Plac/None: Placebo or no intervention; Prop: Propofol; Rhyth: Rhythim. \n\n\n\n\nDexmedetomidine\n Figure 3. Dexmedetomidine compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias; +: low risk of bias; ?: some concerns; - high risk of bias.\n\n\n\n\n\n\n\n Figure 4. Dexmedetomidine compared with placebo or no intervention — trials from China vs. other countries. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias; +: low risk of bias; ?: some concerns; - high risk of bias.\n\n\n\n\n\n\n\n\n\n Figure 5. Dexmedetomidine compared with placebo or no intervention small study effects — funnel plot and limit meta-analysis. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (95% CI) from random effects models — unadjusted 0.49 (0.37–0.65); adjusted for small study effects: 0.77 (0.50–1.18).\n\n\n\n\n\n\n\n\n\n Figure 6. Summary risk of bias from randomized clinical trials of dexmedetomidine compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKetamine\n Figure 7. Ketamine compared with placebo. \n\n\n\n\n\n\n\n\n\n D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias; +: low risk of bias; ?: some concerns; - high risk of bias.\n\n\n\n\n\n\n\n\n\n\n\n\nMelatonin/Ramelteon\n Figure 9. Melatonin and ramelteon compared with placebo. \n\n\n\n\n\n\n\n\n\n Mel: melatonin; Ram: ramelteon; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias; +: low risk of bias; ?: some concerns; - high risk of bias.\n\n\n\n\n\n\n\n\n\n\n\n\nAll Comparators\n Figure 11. Network meta-analysis including all comparators.\n\n\n\n\n\n\n\n\n\nDex: Dexmedetomidine; Ket: Ketamine; Mel: Melatonin; Ram: Ramelteon; Mid: Midazolam; MS: Morphine; Preg: Pregabalin; Prop: Propofol; Rhyth: Rhythim; Plac/None: Placebo or no comparator.\n\n Table 14. League table of risk ratios and 95% confidence intervals from network meta-analysis (random effects model). Comparisons from direct evidence displayed in the upper diagonal; network comparisons shown on the lower diagonal. \n\n\n\n\n\n  \n  \n  \n    Dex\n\n\n\n0.33(0.11;  0.97)\n\n0.57(0.21;  1.55)\n\n0.70(0.47;  1.04)\n\n0.17(0.02;  1.51)\n\n0.56(0.45;  0.71)\n\n    0.91(0.50;  1.66)\n\nKet\n\n\n\n\n0.56(0.21;  1.46)\n\n\n0.73(0.36;  1.47)\n\n    0.77(0.47;  1.26)\n\n0.85(0.41;  1.77)\n\nMel/Ram\n\n0.21(0.07;  0.69)\n\n\n\n\n0.74(0.48;  1.16)\n\n    0.32(0.16;  0.63)\n\n0.35(0.15;  0.86)\n\n0.42(0.20;  0.89)\n\nMid\n\n\n\n\n1.35(0.54;  3.37)\n\n    0.57(0.21;  1.55)\n\n0.63(0.20;  2.02)\n\n0.74(0.24;  2.26)\n\n1.78(0.53;  5.95)\n\nMS\n\n\n\n\n    0.67(0.46;  0.98)\n\n0.74(0.39;  1.39)\n\n0.87(0.47;  1.60)\n\n2.09(0.96;  4.51)\n\n1.18(0.40;  3.42)\n\nProp\n\n\n\n    0.17(0.02;  1.51)\n\n0.18(0.02;  1.80)\n\n0.22(0.02;  2.07)\n\n0.52(0.05;  5.20)\n\n0.29(0.03;  3.28)\n\n0.25(0.03;  2.32)\n\nRhyth\n\n\n    0.57(0.46;  0.71)\n\n0.63(0.35;  1.13)\n\n0.74(0.48;  1.16)\n\n1.78(0.91;  3.48)\n\n1.00(0.36;  2.79)\n\n0.85(0.56;  1.30)\n\n3.43(0.37; 31.47)\n\nPlac/None\n\n  \n  \n  \n    \n       Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin or Ramelteon; Mid: Midazolam; MS: Morphine; Preg: Pregabalin; Prop: Propofol; Rhyth: Rhythim; Plac/None: Placebo or no comparator.\n    \n  \n\n\n\n\n\n\n\n\n\n Figure 12. Comparison adjusted funnel plot. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Figure 13. Comparison of direct and indirect evidence in network meta-analysis (node splitting forest plot). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDex: Dexmedetomidine; Ket: Ketamine; Mel: Melatonin; Ram: Ramelteon; Mid: Midazolam; MS: Morphine; Preg: Pregabalin; Prop: Propofol; Rhyth: Rhythim; Plac/None: Placebo or no comparator."
  },
  {
    "objectID": "kq6.html#delayed-ncrncd",
    "href": "kq6.html#delayed-ncrncd",
    "title": "Delirium Prophylaxis",
    "section": "Delayed NCR/NCD",
    "text": "Delayed NCR/NCD"
  },
  {
    "objectID": "kq6.html#complications",
    "href": "kq6.html#complications",
    "title": "Delirium Prophylaxis",
    "section": "Complications",
    "text": "Complications"
  },
  {
    "objectID": "kq6.html#mortality",
    "href": "kq6.html#mortality",
    "title": "Delirium Prophylaxis",
    "section": "Mortality",
    "text": "Mortality"
  },
  {
    "objectID": "kq6.html#study-characteristics",
    "href": "kq6.html#study-characteristics",
    "title": "Delirium Prophylaxis",
    "section": "Study Characteristics",
    "text": "Study Characteristics"
  },
  {
    "objectID": "kq6.html#risk-of-bias",
    "href": "kq6.html#risk-of-bias",
    "title": "Delirium Prophylaxis",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n Figure 14. Summary risk of bias assessment for all included randomized clinical trials. \n\n\n\n\n\n Figure 15. Risk of bias assessment for randomized clinical trials."
  },
  {
    "objectID": "soe_gt.html",
    "href": "soe_gt.html",
    "title": "Strength of Evidence",
    "section": "",
    "text": "Delirium Prophylaxis\n\n\nStrength of Evidence Ratings\n\n Table 1. Strength of evidence for outcomes relevant to delirium prophylaxis. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n  \n    \n      Outcome\n      Studies (Pts)\n      GRADEa\n      ACCF AHA\n      Importanceb\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium  (Incidence Proportion)\n\n19 (6084)\n\n⨁⨁◯◯\n\nB-R\n+++\nPooled estimate from 19 RCTs suggested less post-operative delirium with dexmedetomidine compared with placebo or no active comparator, but small study effects and inconstency appeared likely.  RR 0.57  (95% CI, 0.46–0.71; I2 64%) (Network meta-analysis results were consistent.)\n\n\n    Delirium  (Incidence Proportion)\n\n3 (803)\n\n\n\n\n\n\n    Delirium  (Incidence Proportion)\n\n5 (1079)\n\n\n\n\n\n\n  \n  \n  \n    \n       Pts: patients; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio.\n    \n    \n      a Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      b + Limited; ++ Important; +++ Critical."
  }
]